Literature DB >> 9574746

Late onset of haze associated with viral keratoconjunctivitis following photorefractive keratectomy.

R Pineda1, J H Talamo.   

Abstract

BACKGROUND: To report a newly recognized cause of late onset of corneal haze following photorefractive keratectomy (PRK).
METHODS: A 35-year old woman who underwent uneventful PRK and subsequently developed viral keratoconjunctivitis 1 year after treatment.
RESULTS: During resolution of the viral keratoconjunctivitis, the patient developed extensive central corneal subepithelial infiltrates and anterior stromal fibrosis in the PRK ablation zone. More than 1 year after the initial infection, the central subepithelial fibrosis persisted, complicated by myopic regression, central steep island on videokeratography, and loss of five lines of spectacle-corrected visual acuity. By the end of the second year after the infection, visual acuity had improved with disappearance of the central steep island on videokeratography. However, the myopic regression and subepithelial fibrosis remained.
CONCLUSION: Patients who undergo PRK may be at greater risk of visual loss following viral keratoconjunctivitis secondary to persistent subepithelial infiltrates and/or stromal fibrosis within the PRK treatment zone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574746     DOI: 10.3928/1081-597X-19980301-14

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  2 in total

1.  Development of EKC after eximer laser photorefractive surgery and subsequent recurrence of EKC-like keratitis.

Authors:  Sung Joon Park; Yoon Soo Jang; Tae Hyuk Koh; Young A Kwon; Sang Wroul Song
Journal:  Korean J Ophthalmol       Date:  2011-11-22

2.  Very late onset corneal haze in a photorefractive keratectomy patient associated with presumed viral keratoconjuctivitis.

Authors:  Karmiris Efthymios; Machairoudia Genovefa; Armenis John; Magoulas Michael
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.